ADMA — ADMA Biologics, Inc. (Stock)

Price: $10.73 · 1 day: +3.77% · 5 days: +3.87% · 1 month: +24.62% · YTD: -41.17%
As of 2026-10-15 20:00 UTC.

52-week range: $7.21 – $20.46 (currently at 27% of the range).

The brief

ADMA is in a turning down, momentum firm. $11 is the level overhead; $10 the first support below.

4 of 6 technical checks lean bullish.

• Price vs 50-day: above
• Price vs 200-day: below
• 50d vs 200d avg: below
• MACD: bullish
• RSI momentum: 75
• 5-day tape: +3.9%

Key levels

Indicators

Next earnings: 2026-11-04.

Latest ADMA news

• FDA Grants Orphan Drug Designation to Kedrion's QIVIGY® for Stiff Person Syndrome, an Ultra-Rare Neurological Disorder — Kedrion Biopharma announced that the FDA has granted Orphan Drug Designation to QIVIGY for the treatment of Stiff Person Syndrome (SPS), an ultra-rare neurological disorder affecting approximately two per 100,000 people. (PR Newswire, 2026-09-22)
• Berger Montague PC Investigates ADMA Biologics, Inc.'s Board of Directors for Breach of Fiduciary Duty (NASDAQ: ADMA) — Berger Montague PC has launched an investigation into ADMA Biologics, Inc.'s Board of Directors for potential breaches of fiduciary duty, focusing on whether the company engaged in channel-stuffing to artificially boost (PR Newswire, 2026-09-08)
• Berger Montague PC Investigates ADMA Biologics, Inc.'s Board of Directors for Breach of Fiduciary Duty (NASDAQ: ADMA) — Berger Montague PC has launched an investigation into ADMA Biologics, Inc.'s Board of Directors for potential breaches of fiduciary duty. The probe focuses on whether the company engaged in channel-stuffing to artificial (PR Newswire, 2026-08-31)
• ADMA Biologics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - ADMA — ADMA Biologics, Inc. (NASDAQ: ADMA) is facing a class action lawsuit for alleged securities law violations under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. The class period runs from August 9, 2024, (PR Newswire, 2026-08-21)
• ADMA Investors Have Opportunity to Lead ADMA Biologics, Inc. Securities Fraud Lawsuit with SBS Law — A securities fraud class action lawsuit has been filed against ADMA Biologics, Inc. (NASDAQ: ADMA) for alleged violations of the Securities Exchange Act of 1934. The complaint claims the company made false and misleading (PR Newswire, 2026-08-21)
• ADMA BIOLOGICS, INC. — Quarterly report (10-Q) — ADMA Biologics, Inc. filed its quarterly report on Form 10-Q with the SEC on August 5, 2026, for the second quarter of fiscal year 2026 ended June 30, 2026. The company reported revenue of $124.4 million, representing a (SEC EDGAR, 2026-08-05)
• ADMA BIOLOGICS, INC. — Form 8-K: 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits — ADMA Biologics, Inc. filed a Form 8-K with the U.S. Securities and Exchange Commission on August 5, 2026. The filing covers Item 2.02, Results of Operations and Financial Condition, and Item 9.01, Financial Statements an (SEC EDGAR, 2026-08-05)
• ADMA AUGUST 10, 2026 DEADLINE: ADMA Biologics, Inc. Investors Have Opportunity to Lead Class Action Lawsuit- HBSS — Hagens Berman has filed a securities fraud class action lawsuit against ADMA Biologics, Inc. (NASDAQ: ADMA), alleging the company misrepresented its financial condition, revenue recognition, and inventory distribution. T (PR Newswire, 2026-07-31)

Explore more

Interactive ADMA chart and analyst chat · Market terminal — movers, signals and news · Use MarketCrew inside Claude · Use MarketCrew inside ChatGPT · Top gainers today · 52-week highs